This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

NINDS rt-PA Stroke Study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.

624 patients with iscahemic stroke were treated with 0.9 mg/kg (max 90 mg) rt-PA within 3 hours after the onset of symptoms. Half of the patients received treatment within 90 minutes.

Of the rt-PA treated patients 31-50% had complete or near-complete recovery at 3 months compared with 20-38% given placebo. This benefit was similar at 1 year.

The main hazard was of symptomatic cerebral haemorrhage in 6.4% of the treatment group compared with 0.6% in the placebo group. Indiviuduals with a more severe intial neurological defect or mass effect on the baseline CT scan were at greater risk of this complication.

Mortality was similar in both groups rt-PA vs placebo, at 3 months 17% vs 20%, at 1 year 24% vs 28%.

Reference:

  • (1) Brott, Bogousslavsky (2000). Treatment of acute ischaemic stroke. NEJM, 343, 710-722

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.